A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer

This study is a Phase 2, open-label,multicenter study designed to evaluate the efficacy and safety of 9MW2821monotherapy or combined with PD-1 inhibitor in locally advanced or metastatic Triple-Negative Breast Cancer.

Trial Details

NCT ID
NCT06492005
Phase
PHASE2
Sponsor
Mabwell (Shanghai) Bioscience Co., Ltd.
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • 9MW2821
  • PD-1 inhibitior
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Competent to comprehend, sign, and date an independent ethics committee/institutional review board/research ethics board (IEC/IRB/REB) approved inf…
  • Male or female subjects aged 18 to 75 years (including 18 and 75 years).
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Histopathological diagnosed of locally advanced or metastatic triple negative breast cancer. Not suitable for radical therapy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →